Danforth Advisors LLC, today announced the acquisition of PharmaDirections, Inc., a full-spectrum development partner to life science companies, expanding its integrated capabilities from discovery through commercialization.
Founded in 2003, PharmaDirections was a pioneer of the virtual drug development model. The company brings veteran program leaders and more than 150 specialists to support strategic planning and execution from company incubation to approval. The team’s expertise spans discovery, early to late stage non-clinical and clinical development, translational sciences, and all areas of CMC with full program and alliance management oversight across all major modalities and therapeutic areas. Michelle Higgin, PhD, will continue in her role as CEO.
“PharmaDirections and Danforth share more than capabilities – we share a philosophy of partnership and problem-solving for life science companies,” said Chris Connors, CEO of Danforth Advisors. “By bringing our teams together, we’re creating a unified resource that helps innovators overcome the most complex challenges in drug development while keeping the mission – getting new therapies to patients – at the heart of everything we do.”
“For more than 20 years, it’s been our privilege to partner strategically and operationally with outstanding biotech companies developing state of the art therapies. Joining forces with Danforth expands our platform to build, grow, and sustain successful businesses beyond just the science,” said Dr. Higgin. “Whether clients need to scale rapidly, secure funding, or manage complex programs, we will work collectively to deliver the right expertise at the right time.”
With this acquisition, Danforth can provide deep drug development expertise across all stages – from discovery through approval – covering the critical functional areas of discovery research, non-clinical, manufacturing, project management, translational research, clinical operations, medical writing, regulatory strategy, and publishing. PharmaDirections adds to the previous acquisitions of Elite BioPharma Consulting (Clinical Operations) and Advyzom (Regulatory), enabling Danforth to provide integrated teams who support clients seamlessly, flexibly, and collaboratively to successfully deliver on drug development and regulatory milestones.
PharmaDirections is the sixth organization to join Danforth, following the acquisitions of VPMR, Advyzom, and BW Health Group in 2024, Elite BioPharma Consulting in 2023, and Argot Partners in 2022. In December 2021, Danforth announced an investment by Avesi Partners, LLC, to accelerate plans to meet an ever-broadening scope of strategic and operational needs for life science companies. By uniting the capabilities of its affiliates, Danforth provides cohesive strategies, accelerates execution, and delivers streamlined support across business, clinical, and commercial functions.
Read more here.